test

Solid Tumors

10
A Phase 1b Study Of The 4-1bb Agonist Pf-05082566 In Combination With The Pd-1 Inhibitor Mk-3475 In Patients With Advanced Solid Tumors
Principal Investigator: Mario Sznol
A Phase I Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Disease/Condition: Anus | Bladder | Breast - Female | Breast - Male | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Liver | Lung | Other Digestive Organ | Other Endocrine System | Other Female Genital | Other Male Genital | Other Respiratory and Intrathoracic Organs
Principal Investigator: Lajos Pusztai
A Phase I Study of MEDI6383 (an OX40 Agonist) in Adult Subjects With Select Advanced Solid Tumors
Disease/Condition: Bladder | Colon | Lip, Oral Cavity and Pharynx | Lung
Principal Investigator: Joseph Paul Eder
A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumors
Disease/Condition: Breast - Female | Colon | Esophagus | Kidney | Liver | Lung | Melanoma, skin | Other Skin | Pancreas
Principal Investigator: Joseph Paul Eder
A Phase I, Open-label, dose-escalation study of the safety and pharmacokinetics of MPDL3280A administered intravenously as a single agent to patients with locally advanced or metastatic solid tumors or hematologic malignancies
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Cervix Uteri | Colon | Esophagus | Kidney | Larynx | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Multiple Myeloma | Non-Hodgkin's Lymphoma | Other Female Genital | Other Male Genital | Pancreas | Prostate | Rectum | Soft Tissue | Stomach | Thyroid
Principal Investigator: Roy Herbst
A Phase I, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects with Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Disease/Condition: Bladder | Breast - Female | Colon | Lung | Melanoma, skin | Other Endocrine System | Other Respiratory and Intrathoracic Organs | Other Urinary | Ovary | Rectum | Stomach
Principal Investigator: Joseph Paul Eder
A Phase I/II Study of the Combination of BKM120 and Bevacizumab, Glioblastoma Multiforme
Disease/Condition: Brain and Nervous System
Principal Investigator: Kevin Becker
A Phase Ib, Open-label Study of Oral BGJ398 in Combination With Oral BYL719 in Adult Patients With Select Advanced Solid Tumors
Disease/Condition: Bladder
Principal Investigator: Daniel Petrylak
A Two Part, Phase I, Multicenter, Open-label Study of TEN-010 Given Subcutaneously Part A: A Dose-Escalation Study in Patients with Advanced Solid Tumors Part B: An Expansion Cohort in Patients with Selected Malignancies
Disease/Condition: Bladder | Breast - Female | Colon | Esophagus | Kidney | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Pancreas | Soft Tissue | Stomach
Principal Investigator: Joseph Paul Eder
An Open Label Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose of the Anti-mesothelin Antibody Drug Conjugate BAY94-9343 in Subjects With Advanced Solid Tumors
Principal Investigator: Alessandro Santin
An Open-label, Phase I, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0575 Administered Alone and in Combination With Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma
Disease/Condition: Breast - Female | Lung | Ovary
Principal Investigator: Joseph Paul Eder
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors
Disease/Condition: Other Digestive Organ | Unknown Sites
Principal Investigator: Joseph Paul Eder
My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Cancer with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents PRO-02
Disease/Condition: Bladder | Brain and Nervous System | Breast - Female | Colon | Esophagus | Lip, Oral Cavity and Pharynx | Liver | Lung | Melanoma, skin | Other Endocrine System | Ovary | Pancreas | Prostate | Rectum | Small Intestine | Soft Tissue | Stomach | Thyroid
Principal Investigator: Joseph Paul Eder
Phase Ib Trial of MPDL3280A with Bevacizumab or with Bevacizumab + FOLFOX in Patients with Solid Tumors
Disease/Condition: Colon | Lung | Rectum
Principal Investigator: Howard Hochster